A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Nicotine DependenceOverweightObesity
Interventions
DRUG

NB32

All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.

BEHAVIORAL

Ancillary therapy

During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.

Trial Locations (3)

90720

Pharmacology Research Institute, Los Alamitos

91316

Pharmacology Research Institute, Encino

92660

Pharmacology Research Institute, Newport Beach

Sponsors
All Listed Sponsors
lead

Orexigen Therapeutics, Inc

INDUSTRY